secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2024-05-21T23:59:59+00:00
Accession:  0001549595-24-000073
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix Therapeutics annual meeting: stockholders elect directors, ratify auditor, approve say-on-pay
--------------------------------------------------------------------------------

- Stockholders elected directors Julia P. Gregory (29.9M for, 4.5M withheld) and David L. Lacey (27.1M for, 7.3M withheld) to terms expiring 2027.
- Ratified PricewaterhouseCoopers LLP as independent auditor for FY ending Nov 30, 2024 (39.0M for, 16.7K against).
- Non-binding advisory vote on named executive officer compensation passed: 30.4M for, 4.0M against, 77.4K abstentions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000073/0001549595-24-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959524000073/nrix-20240520.htm
  HTML page:      https://secwatch.observer/filing/0001549595-24-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer